Each week, a professional investor tells MoneyWeek where he’d put his money now. This week: Dr Daniel Koller, head of BB Biotech, Bellevue Asset Management.
The biotechnology sector has reached a certain level of maturity. In the early years, the only companies that investors had to choose from were highly speculative punts in small unproven start-ups. These days there is a wide range of profitable and well-run biotech companies to invest in.
Most of them are headquartered in the US and listed on the tech-focused Nasdaq stock exchange.
These companies have made great progress in clinical research and development over [...]
Want to read this article now?
Already a MoneyWeek subscriber? Please log in below.
Not a subscriber? Sign-up now for a 4 week FREE trial to get instant access.